News

Jon Hu Forbes Councils Member Everyone likes to point fingers at big pharma. They’ll point to how much money it takes to develop a single drug (up to $2.8 billion on average)—or point to how a drug caused severe, long-term side effects that result in it coming off the market—ultimately throwing that money down the drain. But ironically, they’re missing the point. The problem isn’t the cost; the cost is an effect…

The drug discovery firm will work with the Dean Felsher laboratory, using the company's transomics platform to discover therapies for untreatable cancers. Researchers at Stanford University's Dean Felsher laboratory have announced plans to collaborate with drug discovery company Pepper Bio in an effort to identify therapeutic targets for untreatable lymphatic and liver cancers. With the help of Pepper Bio's platform on phosphoproteomics, the collaborators reportedly aim to identify and validate…

There’s a clear pain point when it comes to drug discovery: Depending on which study you cite, creating an approved drug costs anywhere from $985 million to $2.6 billion. And R&D returns have rebounded to only about 2.5% in 2020, up from a low of 1.6% in 2019. Not to mention the fact that drugs that fail in clinical trials don’t actually help people who need new treatments. With a…